Drug Safety, Access and Regulatory Evidence

How this evidence desk works

This desk explains what an official record establishes, which identifiers control its scope and what must be rechecked before a time-sensitive claim is published.

For a practical example, our guide to checking the product behind the Cialis Professional name connects ingredient evidence with the manufacturer, tablet form and pack details a reader needs to clarify. The Priligy appointment guide applies those checks to a patient leaflet and the questions a reader can bring to a clinician. For the research behind treatment claims, our dapoxetine evidence guide explains how benefits, adverse effects and study limitations belong in the same assessment.

Source

Begin with the controlling agency record or primary dataset.

Scope

Preserve population, setting, product, geography and time.

Boundary

State what the evidence cannot establish or recommend.

Refresh

Recheck dynamic records before time-sensitive publication.

Research index

Evidence guides in this desk

• 
  Evidence guide 26
  Reading FDA Drug Safety Communications Without Overreach
  Read an FDA Drug Safety Communication by scope, evidence, status and audience without turning agency language into medical advice.
  
• 
  Evidence guide 27
  How to Report a Verified FDA Label Safety Change
  Compare dated Drugs@FDA labeling records before reporting a safety change, and keep future-event claims on hold until verified.
  
• 
  Evidence guide 28
  What the Current FDA Drug Shortage Database Shows
  Verify one exact FDA shortage record, product presentation and status while keeping national data separate from local inventory.
  
• 
  Evidence guide 29
  How to Distinguish an FDA Shortage From a Local Stock Issue
  Separate an FDA-listed national shortage from a local pharmacy stock issue using the right source, product presentation and timestamp.
  
• 
  Evidence guide 30
  Reading an FDA Drug Recall Classification and Scope
  Verify product, lot, firm, geography and FDA classification before reporting a recall, and do not extend it to unaffected supply.
  
• 
  Evidence guide 31
  How FDA MedWatch Reports Become Safety Questions
  Understand how MedWatch reports support surveillance without proving causation, incidence or comparative drug risk.
  
• 
  Evidence guide 32
  What FAERS Data Can and Cannot Prove
  Use the current FDA AEMS dashboard, formerly FAERS, without estimating incidence, causation or drug-safety rankings from reports.
  
• 
  Evidence guide 33
  How to Verify Current REMS Requirements
  Find the exact current FDA REMS record, participant roles and modification dates without copying requirements between programs.
  
• 
  Evidence guide 34
  What a Verified FDA Boxed Warning Update Means
  Compare two dated FDA labels and the application action before reporting a boxed-warning change or interpreting its scope.
  
• 
  Evidence guide 35
  How to Find and Read an Official Medication Guide
  Find a current FDA Medication Guide through the matching product application and avoid relying on an authentic but outdated copy.
  
• 
  Evidence guide 36
  Reading FDA Orange Book Codes Without Recommending a Substitute
  Read FDA Orange Book therapeutic-equivalence codes with ingredient, route, strength and product context without directing substitution.
  
• 
  Evidence guide 37
  Using the FDA Purple Book for Biologic Product Questions
  Verify biosimilar and interchangeable status in the FDA Purple Book without treating the two terms as synonyms or medical advice.
  
• 
  Evidence guide 38
  Reading a Verified FDA Alert About Compounded Drugs
  Report an FDA compounding alert by exact preparation, concern, audience and agency language without generalizing to all products.
  
• 
  Evidence guide 39
  What a Current FDA Counterfeit Product Alert Covers
  Verify an FDA counterfeit-product alert by exact identifiers, scope and agency instructions without accusing unlisted supply or sellers.
  
• 
  Evidence guide 40
  Choosing the Right FDA Source for a Drug Safety Claim
  Choose among FDA alerts, safety communications, recalls, shortage records, Drugs@FDA and surveillance data by claim type.
  
• 
  Evidence guide 41
  Reading a Resolved Status in the FDA Drug Shortage Database
  Learn what a resolved FDA shortage status means nationally, why local stock may lag and which exact product details must be verified.
  
• 
  Evidence guide 42
  How to Read an FDA Drug Manufacturing Warning Letter
  Read an FDA manufacturing warning letter by recipient, scope, observations and later status without turning it into a recall claim.
  
• 
  Evidence guide 43
  Reading a Verified Pediatric Drug Label Update
  Report an FDA pediatric label update with the exact product, ages, indication, evidence and current label without inferring dosing.
  
• 
  Evidence guide 44
  How to Report FDA Pregnancy and Lactation Labeling Accurately
  Read FDA pregnancy and lactation label sections by current product, risk summary, clinical considerations and evidence limits.
  
• 
  Evidence guide 45
  Which Official Record Should Anchor a Drug Safety Story
  Choose the right FDA label, safety communication, recall, alert, shortage or surveillance source for each drug-safety claim.
  
• Evidence analysis 111Human vs Veterinary Ivermectin: Product BoundariesCompare intended species, formulations, labeling and dispensing before treating products as interchangeable.
• Evidence analysis 112Clomiphene Off-Label Use: What Monitoring Must ConfirmSeparate the approved label from documented off-label decisions, monitoring and warning signs.
• 
  Evidence guide 115
  Cialis Professional: Check the Product Behind the Name
  Match the product name, ingredient, tablet form and supplied pack before applying tadalafil evidence or comparing prices.
  
• 
  Evidence guide 118
  Priligy Information: Prepare for a Clinical Conversation
  Check the product record and patient leaflet, then prepare a medication history and specific questions for an appointment.
  
• 
  Evidence guide 119
  Dapoxetine Evidence: Read Benefits and Risks Together
  Read trial outcomes with the comparison group, adverse effects and follow-up period before applying a result to an individual.